A new study titled the 2026 Korea Wellness Report, released by KB Financial Group, highlights a notable trend in the usage of GLP-1 weight-loss drugs within South Korea. According to the survey, which polled 2,000 men and women between the ages of 25 and 69, the adoption of these medications is particularly high among younger adults. Data indicates that roughly 16.7 percent—or one in six—respondents belonging to the Gen Z generation reported having used or been prescribed these drugs over the course of 2025.

When looking at the broader population, the survey found that the overall uptake of weight-loss medication across all surveyed age brackets was 10.3 percent. The research, conducted between July and August, suggests that the popularity of these treatments is growing, with younger demographics showing a higher propensity for utilizing medical interventions for weight management compared to their older counterparts. While the report provides a snapshot of current usage patterns, it does not detail the specific medical justifications or the long-term health implications associated with this level of consumption among the younger population. The findings underscore a shift in wellness trends within the country, as GLP-1 drugs—originally developed for diabetes management—continue to gain traction as a weight-loss solution in the South Korean market.